Les traitements immunosuppresseurs pour un futur immédiat.

Transcription

1 Les traitements immunosuppresseurs pour un futur immédiat. Henri Kreis Université Paris V & Hôpital Necker, Paris DIU Transplantation Tours, 7-9 janvier 2009

2 Graft survival at one year Immunosuppression effect? 100% 50% Improved short-term graft survival

3 Post-RT mortality (6 months) Hôpital Necker Immunosuppression effect? < 1% Avoiding short term patients death 2004

4 Acute rejection incidence Acute rejection (%) Acute rejection months 6-12 months 0-6 months Meier-Kriesche HU, 2004 Am J Transplant Transplant year Decreasing the incidence of acute rejection How does it impacts graft survival? 6 2.9

5 Causes of late allograft loss Allograft nephropathy Death with a functioning graft M. Pascual, N Engl J Med 2002

6 1. L état des lieux 2. De nouvelles approches 3. Une moindre toxicité 4. La prévention du cancer 5. L individualisation du traitement

7 The «3 signals «

8

9 Antibody induction; adult patients USRDS 2008 First-time, kidney-only transplants, age 18 & older, Immunosuppression as identified to OPTN.

10 Baseline calcineurin inhibitor use; adult patients USRDS 2008 First-time, kidney-only transplants, age 18 & older, Immunosuppression as identified to OPTN. CsA: cyclosporine A; CsM: cyclosporine microemulsion. Tacrolimus includes traditional & modified release formulations.

11 Baseline antimetabolite use; adult patients USRDS 2008 First-time, kidney-only transplants, age 18 & older, Immunosuppression as identified to OPTN. MMF includes mycophenolate mofetil & mycophenolate sodium.

12 mtor inhibitor use; adult patients USRDS 2008 First-time, kidney-only transplants, age 18 & older, Immunosuppression as identified to OPTN. mtor: mammalian target of rapamycin; includes sirolimus & everolimus.

13 Steroid use; adult patients First-time, kidney-only transplants, age 18 & older, Immunosuppression as identified to OPTN. USRDS 2008

14 Most common immunosuppression regimens at time of transplant: ; adult patients USRDS 2008 First-time, kidney-only transplants, Maintenance immunosuppression as identified to OPTN. first-time, kidney-only transplants, age 18 & older, Maintenance immunosuppression as identified to OPTN. CsA: cyclosporine A; CsM: cyclosporine microemulsion. Cyclo includes CsA & CsM. MMF: mycophenolate mofetil & mycophenolate sodium. Tac: tacrolimus; includes traditional & modified release formulations. mtor: mammalian target of rapamycin; includes sirolimus & everolimus.

15 1. L état des lieux 2. De nouvelles approches 3. Une moindre toxicité 4. La prévention du cancer 5. L individualisation du traitement

16 Nouvelles définitions du rejet aigu.

17 C4d - Médiation cellulaire Lymphocyte T Rejet aigu C4d + Médiation humorale Lymphocyte B Ac anti-hla +

18 1. I.V.Igs 2. Anti-CD2O A multicentre phase III study 3. Plasma is currently ongoing with rituximab. exchanges

19 it is suggested to use one or more of the following treatment alternatives, with or without corticosteroids: (Weak) plasma exchange To treat antibody mediated acute intravenous immunoglobulin anti-cd20 antibody rejection lymphocyte-depleting antibody

20

21 Humanized anti-cd3 mabs ChAglyCD3 (TRX4): Friend P et al, Transplantation 1999, huokt3gamma1(ala-ala), Teplizumab: Woodle ES et al, Transplantation 1999, HuM291, Visilizumab: Norman D et al, Transplantation 2000, NI-0401: fully humanized anti-cd3: a French trial in acute rejection.

22 Hill A et al, Br J Haematol 2007

23 Anti-C5 mabs: indications Acute humoral rejection (on going), Chronic humoral rejection, Recurrence of membranoproliferative glomerulonephritis (type2), Atypical HUS,

24 Miscellaneous Slow release anti-cd25, Purine nucleoside phosphorylase inhibitor, Anti-LFA1, Anti-CD28, Velcade, Belimumab,.

25

26

27 PKC θ AEB071

28 AEB071 AEB071: potent and selective inhibitor of PKCs, Several isoforms: classical (α,β), novel (δ,ε,θ,η) and atypical. Isoforms α, β, θ are playing a major role in T is and currently B cell signaling. ongoing. Safety profile: GI tract, Pulse rate, Liver. A multicentre phase II study Slade A et al, A T C 2007

29 1. L état des lieux 2. De nouvelles approches 3. Une moindre toxicité 4. La prévention du cancer 5. L individualisation du traitement

30 CARMEN study Tacro + MMF + steroïds versus Anti-IL2r + tacro + MMF 50 Patient and graft survival, graft function = similar % biopsy proven acute rejection 16.5 n= n=260 CS Resistant Ste + Ste - Ste + Ste - Rostaing L et al, Transplantation 2005

31 Calcineurin inhibitors = But!

32 Nephrotoxicity Hypertension CNIs toxicity Dyslipidemia New-onset diabetes mellitus

33 How to decrease CNIs toxicity? Minimisation Conversion : MMF, mtor-is Avoidance : MMF, mtor-is, belatacept

34

35 What have we learned? Early introduction of sirolimus: With low dose CNIs: concerns delayed graft function (incidence, length)? guidelines? Increased CNIs nephrotoxicity? Without CNIs: concerns acute rejection rate (++ with low dose siro), healing complications, high drop out rate.

36 What have we learned? Secondary introduction of sirolimus: When? Not too early: same as early introduction, Not too late: little benefit with regard to function, Between 3 months and one year? To increase efficacy and safety: Patients with GFR > 40ml/min and low proteinuria, Better? Biopsy, pharmacogenetics The driving force: prevention of cancer!

37

38 CNI avoidance: belatacept

39 ISA247 MR4

40 CsA analog : ISATX247 CsA analog ISATX247: 3 times more potent than CsA and similar toxicity in vitro. Phase IIb: IS247 versus tacro: Preliminary results at 3 months, Acute rejection = similar, Renal function = similar, Safety: less diabetes and tremor. Busque S et al, A T C 2007

41 Extended release tacrolimus Tacro (MR4): non inferiority at one year compared to Tac and Csa (+ Cs- MMF) (Silva HT et al, Am J Transplant 2007). After 2 year follow-up: Acute rejection: 12.5 vs 10.4 vs 16.0, Patient and graft survival similar, Safety profile: no clear benefit / tacro Diabetes: 16.4 vs 11.8 vs 7.1. Yang H et al, A T C 2007

42 1. L état des lieux 2. De nouvelles approches 3. Une moindre toxicité 4. La prévention du cancer 5. L individualisation du traitement

43 Nantes experience Dantal J et al, Lancet 1998 Prospective study «low dose» CsA (75-125ng/ml) versus «normal dose» CsA ( ng/ml). Results: Cancer: 23 versus 37 after 66 months follow-up, Acute rejection: 9 versus 1.

44 STUDY DESIGN 316 Inclusion 0.5 to 10 yrs after renal tx CsA or TAC MMF or AZA Steroids 2:1 Randomization (N = 830) SRL Conversion (n = 555) SRL troughs: 8-20 ng/ml (by chromatographic method) MMF or AZA: Continue or stop Continue Steroids CNI Continuation (n = 275) Continue CsA or TAC (can switch CsA TAC) MMF or AZA: Continue or stop Continue Steroids

45 Incidence of malignancy

46 1. L état des lieux 2. De nouvelles approches 3. Une moindre toxicité 4. La prévention du cancer 5. L individualisation du traitement

47 Individualizing immunosuppression. Immunological risk: - first or subsequent transplantation, - anti-hla immunization, - positive historical cross-match. Cardiovascular risk profile,. Risk of post-transplant diabetes mellitus,. Risk of delayed graft function,. Living related versus deceased donor,. Etc

48 What makes him different?

49 General pathways of metabolism veina. porta Systemic circulation Intestinal lumen Intestinal wall Liver CYP3A P-gp CYP3A P-gp feces Intestinal metabolism Hepatic first-pass

50 D. Anglicheau et al, JASN 2003

51 Tacrolimus and CYP3A5*3 genetic polymorphism P<0.03, Kruskall Wallis P=0.01, Kruskall Wallis Tacrolimus Daily Dose (mg/kg/d) ns ns Concentration / Dose ratio ns < *1/*1 (n = 4) *1/*3 (n = 9) *3/*3 (n = 67) 0 *1/*1 (n = 4) *1/*3 (n = 9) *3/*3 (n = 67) Patients with the CYP3A5*1 allele (i.e. CYP3A5 expressors) require more tacrolimus to reach target predose concentrations compared with CYP3A5*3/*3 genotype (i.e. CYP3A5 non-expressors). Thervet at al. Transplantation 2003:1233.

52 Pour Conclure

53 CNI avoidance: OKT OKT3 Steroids (H or L) Debure A et al, Transplantation 1988

54 Meier-Kriesche HU, 2004 Am J Transplant Very modest improvements!

55 Long term graft survival of kidney transplants in past 20 years Percent Graft Survival HLA-Id Sib Spouse Parent Cadaver Years Posttransplant Kaneku HK et al, Clinical Transplants 2006

56 CsA Peri-Operative Antibiotics Cohen J, et al.j Hosp Infect. 1988,11: Platt R. Rev Infect Dis. 1984,6 Suppl 4:S Keighley MR. Br Med J. 1983, 286: Kasiske BL, et al. Urol Clin North Am. 1983,10: Kissel SM, et al. N Y State J Med. 1982,82: Shapiro M. Infect Control. 1982, 3: Townsend TR, et al. Infect Control. 1980,1:93-6. Polk HC Jr, et al.jama Sep 19;244: Hurley DL, et al. Surg Clin North Am. 1979,59: Barber MS, et al. Surgery. 1979,86:23-9. Phelan JP, et al. Am J Obstet Gynecol. 1979,133: Prophylactic Anti-CMV Agent Erice A, Jordan MC, Chace BA, Fletcher C, Chinnock BJ, Balfour HH Jr. Ganciclovir treatment of cytomegalovirus disease in transplant recipients and other immunocompromised hosts. JAMA. 1987,257: Pettersson E, Hovi T, Ahonen J, Fiddian AP, Salmela K, Hockerstedt K, Eklund B, von Willebrand E, Hayry P. Prophylactic oral acyclovir after renal transplantation. Transplantation. 1985,39:

57 Il n'est pire sourd Merci de votre attention! que celui qui ne veut pas entendre DIU Transplantation Tours, 7-9 janvier 2009